首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America. >p31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase
【24h】

p31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase

机译:p31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase

获取原文
获取原文并翻译 | 示例
       

摘要

The repair of DNA double strand breaks (DSBs) that arise from external mutagenic agents and routine cellular processes is essential for life. DSBs are repaired by two major pathways, homologous recombination (HR) and classical nonhomologous end joining (C-NHEJ). DSB repair pathway choice is largely dictated at the step of 5'-3' DNA end resection, which is promoted during S phase, in part by BRCA1. Opposing end resection is the 53BP1 protein, which recruits the ssDNA-binding REV7-Shieldin complex to favor C-NHEJ repair. We recently identified TRIP13 as a proresection factor that remodels REV7, causing its dissociation from the Shieldin subunit SHLD3. Here, we identify p31(comet), a negative regulator of MAD2 and the spindle assembly checkpoint, as an important mediator of the TRIP13-REV7 interaction. p31(comet) binds to the REV7-Shieldin complex in cells, promotes REV7 inactivation, and causes PARP inhibitor resistance. p31(comet) also participates in the extraction of REV7 from the chromatin. Furthermore, p31(comet) can counteract REV7 function in translesion synthesis (TLS) by releasing it from REV3 in the Pol complex. Finally, p31(comet), like TRIP13, is overexpressed in many cancers and this correlates with poor prognosis. Thus, we reveal a key player in the regulation of HR and TLS with significant clinical implications.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号